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Embryo-like features of 
induced pluripotent stem 
cells defy legal and ethical 
boundaries
Stem cell science has undergone major paradigmatic and 
technological transformations following the successes 
made in reprogramming mature cells to become pluripo-
tent stem cells; a process which is still under way. This article 
in a series of articles about bio-objects (1) discusses stem 
cell science and how the question of ethical panacea can 
be elaborated in the case of induced pluripotent stem (IPS) 
cells. The stem cells challenge the boundaries (2), which are 
at play in deriving, applying, and regulating the use of iPS 
cells. The recent novelty of reprogramming cells not in vitro 
but in vivo has implications in the demarcation of totipo-
tency from pluripotency in cellular capacities. This in turn 
complicates the perspective of iPS cells as an ethical pana-
cea to biomedical research on human biological material.
THE LATEST PROMISE TO REGENERATIVE MEDICINE: IPS 
CELLS
Ethical discussions on regenerative medicine and, specifi-
cally on the promises of stem cell science, have largely fo-
cused on controversies introduced by stem cells of embry-
onic origin. This is due to the fact that human stem cells 
have been derived from embryos donated by couples un-
dergoing in vitro fertilization (IVF) treatment, from donated 
oocytes, or from aborted fetuses. In this article, we discuss 
ethical aspects emergent in stem cell science following the 
successes made in reprogramming “adult” cells to become 
pluripotent stem cells, not only in vitro but also in vivo. The 
generation of iPC cells has been a major scientific event, 
receiving worldwide public attention through, for exam-
ple, the Nobel Prize in Physiology or Medicine which was 
awarded in 2012 to John B. Gurdon and Shinya Yamanaka 
for their work in the field of cell reprogramming.
Reprogramming cells in vitro has been welcomed as a rev-
olutionary technique that “turns back the developmental 
clock” of human cell development (3,4). This offers new, 
even unforeseen possibilities in disease modeling and drug 
discovery. Much of the excitement surrounding iPS cells in 
basic research, but also in the pharmaceutical industry, 
concerns what is called a “disease on a dish” approach. By 
this approach scientists refer to the process whereby stem 
cells lines in vitro are used to unravel the genetic mecha-
nisms of disease (5,6).
BOuNDARy-wORk ON THE ETHICALITy Of IPS CELLS
Since its beginning, the “stem cell debate” has been pre-
dominantly focused on the treatment of embryos as re-
search subjects, on concern about harm to embryos, con-
cern about the potential exploitation of women for their 
ova, and concern about harm to respect for human life, 
fuelled by the possibilities of commodification (7). In the 
recent history, regenerative medicine seemed to be at an 
uneasy junction. On the one hand, the possibility of gener-
ating human cell lines using embryonic stem cells or cells 
created via somatic cell nuclear transfer was a solid sci-
entific possibility. Even if experiments had demonstrated 
that clinical applications based on these cell lines would 
not materialize in the near future due to, for example, the 
risk of tumorgenecity, there were high expectations about 
their applicability in the future. On the other hand, stem 
cell science was facing the fact that cell lines obtained 
through these techniques involved several ethical, politi-
cal, and legal problems.
Given this situation of both heightened scientific expecta-
tions and ethical tensions, leading to differing policies and 
regulations worldwide, the work published by Japanese 
researchers Kazutoshi Takahashi and Shinya Yamanaka 
opened a new venue in stem cell research. In brief, they 
demonstrated that the forced expression of only four 
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transcription factors, Oct3/4, Sox2, c-Myc, and Klf4, was suffi-
cient to convert mouse fibroblast cells into embryonic stem 
cell-like cells (8). Many subsequent articles then confirmed 
that the timed expression of these factors can change differ-
entiated cells into iPS cells also with human cells (9).
From the perspective of demarcating ethical from non-
ethical practices within stem cell research, the possibility 
of creating pluripotent stem cells without destroying a hu-
man embryo in the process has been welcomed by sci-
entists and bioethicists alike. iPS cells alleviate researchers’ 
dependency on donated embryos and thus are said to by-
pass ethical problems with research on embryonic tissue. 
Indeed, iPS cells have been pictured in scientific journals as 
well as public media as a panacea to the development of 
stem cell science and regenerative medicine.
Regarding stem cell research and ethics, the principle of 
safeguarding the dignity and integrity of the person vis-à-
vis patentability and thus commercialization of inventions 
based on human biological material is inscribed into the Eu-
ropean patent law. However, the case of iPS cells offers an 
interesting view into this rationale. A definitive green light 
to the patentability of products and processes drawing from 
iPS cells came from the legal framework provided by the Eu-
ropean Court of Justice some years ago. On the October 18, 
2011 the European Court of Justice ruled on the Oliver Brüs-
tle vs Greenpeace case, stating that within the meaning of 
Article 6[2][c] of Directive 98/44/EC of the European Parlia-
ment “any human ovum after fertilization, any non-fertilized 
human ovum into which the cell nucleus from a mature hu-
man cell has been transplanted and any non-fertilized hu-
man ovum whose division and further development have 
been stimulated by parthenogenesis constitute a ‘human 
embryo’”, and cannot be patented (10).
The reason was clearly indicated in the same document: 
“Although those organisms have not, strictly speaking, 
been the object of fertilisation, due to the effect of the 
technique used to obtain them they are, as is apparent 
from the written observations presented to the Court, ca-
pable of commencing the process of development of a 
human being just as an embryo created by fertilisation of 
an ovum can do so.” This statement involved an immedi-
ate ban on patents on stem cells produced not only using 
surplus embryos from IVF but also via somatic-cell nuclear 
transfer (SCNT) or via parthenogenesis. Furthermore, the 
Court interpreted the Directive 98/44/EC to mean that 
an invention has to be excluded from patentability if 
it involves the prior destruction of human embryos 
or their use as base material, whatever the stage at which 
this takes place.
At the same time, however, the ruling of the European Court 
of Justice left the door open to patents on iPS cells. The way 
the Court formulated its ruling provided the possibility to 
patent pluripotent cell lines or products derived from them. 
The exclusion from patentability concerned the use of toti-
potent and pluripotent stem cells, the derival of which in-
volves the destruction of human embryos. Thus, it fixed its 
definition of totipotency to human embryonic stem (hES) 
cells. The ruling is based on the presumption that totipotent 
stem cells cannot be technologically created that is, derived 
through other means than from embryonic tissue. However, 
this presumption has become arguable, given the scientific 
finding in stem cell science we will discuss next.
PLuRIPOTENT OR TOTIPOTENT CELLS? A NEw ETHICAL 
CHALLENGE ARISES fROM CuLTIVATING IPS CELLS IN 
VIVO
Since scientific development is often quite unpredict-
able, what seems to be a long-term agreement might be 
challenged sooner than we expect. In September 2013, a 
Spanish team working in the Oncologic Research National 
Centre (CNIO) published in Nature an article that has some 
puzzling implications (11). It reported that researchers had 
managed to cultivate iPS cells in vivo within murine tissue 
using the same reprogramming technique usually applied 
to derive iPS cells in vitro. The core finding presented in the 
article is that in vivo iPS cells are extremely similar to em-
bryonic stem cells. Furthermore, according to the authors 
they are clearly different from in vitro iPS cells.
Regarding the focus of our essay on ethical boundary-
making pertaining to iPS cells, this article by Abad et al 
(2013) invokes an interesting perspective to the presump-
tion presented above that totipotent stem cells can only 
be derived from embryos (11). The article states that in 
mice, in vivo iPS cells present a remarkable capacity to un-
dergo trophectoderm lineage differentiation. This means 
that they possess an unprecedented capacity to produce 
embryo-like structures. The researchers conclude that in 
vivo reprogramming allows the acquisition of totipotency 
features that are absent in ES cells or in standard in vitro re-
programmed iPS cells (12).
This finding, we suggest, has implications for the demarca-
tion of totipotency from pluripotency in stem cells. What 
we are facing here is a conceptual problem. It is reason-
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able to ask, does it make sense to talk about pluripotent 
stem cells if we are dealing with cell lines with totipoten-
cy features; cells that seem to be much more similar to ES 
cells than to iPS cells produced in vitro. If it is ultimately the 
technique that defines the status of the cell (as in Brüstle 
vs Greenpeace case), it seems clear that in vivo iPS cells 
should be considered to be pluripotent cells. But, in do-
ing so, are we committing a nominalist mistake that in the 
long term might have unanticipated consequences? If 
these cells include features of totipotency, should they be 
identified and defined as such? Or, will there arise a need 
for an intermediate term characterizing those cells whose 
characteristics land between pluri- and totipotency?
CONCLuSION
In her discussion on the difficulties of demonstrating the 
moral difference between iPS cells, hES cells and embry-
os, Katrien Devolder (2009) points out that if the human 
embryo is regarded as morally important by the virtue of 
its potential to become a human being, then every other 
cell or group of cells with a similar potential should be as-
signed equal moral status. If not, it should be admitted that 
early embryos do not derive their significance from the po-
tential they possess (13). Following this line of thought, our 
discussion underlines the fact that regarding iPS cells as an 
ethical panacea to biomedical research and commercial-
ization on human biological material is a narrow perspec-
tive to the recent developments in stem cell research and, 
as such, highly problematic.
Given the plasticity of stem cells, the question of how to 
define the moral and legal status of iPS cells will become 
unavoidable, not least because the patent landscape in this 
field remains largely undefined although it is picking up 
globally (14). Furthermore, the ethical boundary-making in 
the case of iPS cells is a topical subject of study, since the 
cells themselves are bio-objects in-the-making, following 
the conceptual work in the previous essays of this series (15). 
As bio-objects of such fluctuating quality, iPS cells point to 
the observation that boundaries pertaining to human bio-
logical material – be they ethical, legal, social, or conceptual 
– are extremely difficult to keep in the long term. Indeed, the 
need to re-formulate them seems constant.
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